Drug Discovery

For decades, the fundamental understanding of the human immune system relied on a strict division of labor where specific molecules directed the activities of specialized cellular defenders against pathogens and tumors. This biological framework, often referred to as the MHC dichotomy, suggested

The high-stakes environment of modern drug discovery often feels like navigating a vast, multidimensional maze where a single structural misstep can derail years of intensive laboratory research. Pharmaceutical scientists frequently grapple with the immense difficulty of predicting how a

The long-standing struggle against small cell neuroendocrine cancers has finally reached a pivotal turning point through the strategic exploitation of genetic dependencies. For over fifty years, patients diagnosed with these aggressive malignancies in the lungs, prostate, or ovaries faced a grim

Ivan Kairatov is a leading biopharma expert with a deep understanding of how generative artificial intelligence is reshaping the landscape of drug development. With extensive experience in research and development, he has been at the forefront of integrating computational biology with traditional

The traditional classification of cancer based primarily on the organ where a tumor first appears is rapidly being superseded by a sophisticated genomic perspective that prioritizes the specific molecular drivers of the disease. Recent breakthroughs led by Dr. Derya Deniz Özdemir and an

Huntington’s disease remains one of the most devastating neurological conditions known to modern medicine, characterized by a relentless decline in both motor control and cognitive function that eventually strips patients of their independence and identity. This genetic disorder stems from a